<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643655</url>
  </required_header>
  <id_info>
    <org_study_id>KSC-MSCs-AVN</org_study_id>
    <nct_id>NCT01643655</nct_id>
  </id_info>
  <brief_title>Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head</brief_title>
  <official_title>Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biostar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biostar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of autologous
      transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with
      avascular necrosis of the femoral head.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic Resonance Imaging</measure>
    <time_frame>96 weeks</time_frame>
    <description>To evaluate the change of treated femoral head using Magnetic Resonance Imaging (MRI) at 24 months post injection of MSCs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPECT/CT</measure>
    <time_frame>96 weeks</time_frame>
    <description>To evaluate the change of treated femoral head using SPEC/CT at 24 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip X-ray</measure>
    <time_frame>96 weeks</time_frame>
    <description>To confirm the collapse of femoral head using Hip X-ray at 24 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HHS (Harris Hip Score)</measure>
    <time_frame>96 weeks</time_frame>
    <description>To evaluate the change of treated femoral head using Harris Hip Score at 24 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC (Western Ontario and McMaster Universities) Index</measure>
    <time_frame>96 weeks</time_frame>
    <description>To evaluate the change of treated femoral head using WOMAC Index at 24 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCLA (University of California Los Angeles) hip questionnaire</measure>
    <time_frame>96 weeks</time_frame>
    <description>To evaluate the change of treated femoral head using UCLA hip questionnaire at 24 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>96 weeks</time_frame>
    <description>To determine the overall safety of Autologous Adipose Tissue Derived Mesenchymal Stem Cells carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Avascular Necrosis of the Femoral Head</condition>
  <arm_group>
    <arm_group_label>Autologous Adipose Tissue Derived MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Adipose Tissue derived MSCs Transplantation</intervention_name>
    <description>Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL</description>
    <arm_group_label>Autologous Adipose Tissue Derived MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age :18-70, males and females.

          -  Subjects who understand and sign the consent form for this study.

          -  Clinical diagnosis of nontraumatic avascular necrosis of the femoral head

          -  Steinberg stage I, II, â…¢A

          -  Patients whose lesion is more than 30% (by Kim's Method)

        Exclusion Criteria:

          -  Patients who have collapsed femoral head

          -  Patient has had a Core Decompression or Multiple Drilling in the affected hip

          -  Patients who received osteoporosis medicines and parathyroid hormone drugs

          -  Taking medications that use the immunosuppressive drugs and cytotoxic agents or unable
             to discontinue their use for the duration of the study

          -  Taking medications that use the adrenocortical hormone drugs or unable to discontinue
             their use for the duration of the study

          -  Subject unable to undergo MRI (i.e. patients with pace-maker, metallic hip prosthetic
             implants)

          -  Women who are pregnant or breast feeding or planning to become pregnant during the
             study.

          -  Positive serology for HIV and hepatitis

          -  Serious pre-existing medical conditions like Cardiovascular Diseases, Cancer, Renal
             Diseases, Endocrine Diseases and Autoimmune Diseases

          -  Participation in another clinical trial or treatment with a different investigational
             product within 3 months prior to inclusion in the study.

          -  Other pathologic conditions or circumstances that difficult participation in the study
             according to medical criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kang-Sup Yoon, M.D. &amp; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

